Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol + Ivabradine vs Carvedilol for LVDD in Cirrhosis
NCT04111133Recruiting
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Jan 2020
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ivabradine in cirrhotic cardiomyopathy (CCM) (2 arms), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoint: Survival at 12 months. Started Jan 2020; status: recruiting.
02
Drugs
ivabradine
03
Conditions
cirrhotic cardiomyopathy (CCM)
Beyond the preview
Go deeper on NCT04111133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04111133.